To the best of our knowledge, dual CD19/HER2 CAR-T cell therapies are not currently under clinical trial for the treatment of NSCLC, but HER2-targeted CAR-T therapies remain an area of active research in this disease. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.